


History of Nippon Shinyaku -As a Pharmaceutical Company from Kyoto-

Nippon Shinyaku has continuously created new, distinctive medicines needed in every era as a research and development-oriented new drug manufacturer to help people lead healthier, happier lives. The foundation of the Company is its venture spirit, which is reflected in the words of the founder, "Making Japanese medicines with Japanese hands." Nippon Shinyaku aims to realize a society where people around the world can live healthily, and will provide valuable products and services.



Founding period–1969

In 1940, Nippon Shinyaku succeeded in manufacturing Santonin in Japan, a vermicide for roundworms, which contributed greatly to the reduction of Japan's roundworm infection rate and to the growth of Nippon Shinyaku's business performance. In the 1960s, Nippon Shinyaku diversified its prescription medicines-related activities by creating new drugs through the expansion of its R&D system, including the completion of a new laboratory for discovering new drugs, and by introducing products through alliances with overseas companies. It also started its Functional Food Business at this time. The Company built its business foundation by completing construction of the Odawara Plant and building a network of sales bases.

1970–1999

Nippon Shinyaku strengthened its R&D structure by establishing the Main Central Research Lab (now Building No. 1 of Discovery Research Laboratories) and other facilities that comply with GLP standards that ensure the safety and appropriateness of non-clinical studies. In the 1990s, the Company opened offices in Germany and the U.S. and promoted globalization through business expansion in Japan, the U.S., and Europe. It launched unique new products in the fields of gastroenterology, cardiology, urology, and otorhinolaryngology, and concentrated business resources into the cultivation of mainstay drugs. In the Functional Food Business, the Company began providing health food ingredients.

2000–2013

In addition to clearly stating its Business Philosophy and Management Policy, Nippon Shinyaku formulated a Medium-Term Management Plan to clarify its corporate vision. It invested business resources in focal areas such as urology and hematology, and invested resources in research on nucleic acid drugs at the Discovery Research Laboratories in Tsukuba. By proactively searching for unmet medical needs, the Company has continuously launched products in areas not often handled by major companies, and some of these products have grown to become business drivers.

2014–Present

Under the theme of "pursuit of originality" set forth in the management strategy of the 5th and 6th Five-Year Medium-Term Management Plans, Nippon Shinyaku has worked to build a unique foundation by continuously launching new products. These include a small molecule compound and a nucleic acid drug discovered in-house that have achieved global expansion, and have led to the establishment and development of a new business model for the Company, such as starting its own marketing by the Group Company NS Pharma in the U.S. The 7th Five-Year Medium-Term Management Plan started in FY2024, and we will continue to promote our global business by prioritizing investments for future growth.

Drug discovery and R&D that continuously pursues patient centricity

